GHRP-6 Side Effects: Hunger, Cortisol & Prolactin

GHRP-6 (Growth Hormone Releasing Peptide-6) is one of the original synthetic growth hormone secretagogues and remains one of the most researched peptides in the GHS family. It's known for two things: potent GH release from the anterior pituitary and significant appetite stimulation — a direct consequence of its action on the ghrelin receptor.

First synthesized in the early 1980s as part of Cyril Bowers' groundbreaking work on growth hormone releasing peptides (Bowers, 1998), GHRP-6 predates the discovery of ghrelin itself and played a key role in identifying the GHS receptor system that would later be recognized as the ghrelin signaling axis (Bowers, 2001).

This guide covers GHRP-6 comprehensively: its mechanism, what makes it different from GHRP-2, dosing protocols from clinical research, benefits beyond GH release, side effects, and practical considerations. For the foundational science on how GHRPs differ from GHRH analogs, see our GHRH vs GHRP mechanistic breakdown.

What Is GHRP-6?

GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. It was one of the first compounds developed to stimulate GH release through a pathway independent of GHRH — what would later be identified as the growth hormone secretagogue receptor (GHSR-1a) or ghrelin receptor.

Key characteristics:

• Molecular weight: ~873 Da
• Half-life: Approximately 15-30 minutes
• Route: Subcutaneous injection (primary research route)
• GH release onset: 15-30 minutes post-administration
• Peak GH levels: 30-60 minutes post-injection
• Distinguishing feature: Strong appetite stimulation via ghrelin receptor activation

GHRP-6 was instrumental in the discovery of the entire ghrelin system. The existence of synthetic peptides that released GH through an unknown receptor led researchers to clone GHSR-1a in 1996 (Howard et al., 1996), and subsequently to identify ghrelin as its endogenous ligand in 1999 (Kojima et al., 1999). As Bowers noted, the "unnatural" peptide led directly to the discovery of the "natural" hormone (Bowers, 2001).

For how GHRP-6 compares directly to GHRP-2 and ipamorelin, see our three-way GHRP comparison.

Mechanism of Action

GHRP-6 acts primarily through the growth hormone secretagogue receptor type 1a (GHSR-1a), a G protein-coupled receptor expressed in the pituitary gland, hypothalamus, and numerous peripheral tissues.

Pituitary GH Release

At the pituitary level, GHRP-6 binding to GHSR-1a on somatotroph cells triggers:

1. Gq/11 protein activation → Phospholipase C (PLC) stimulation
2. IP₃ and DAG generation → Intracellular calcium mobilization from ER stores
3. Protein Kinase C (PKC) activation → Modulation of voltage-gated calcium channels
4. Calcium influx → GH vesicle exocytosis and release

This is the same fundamental signaling cascade used by GHRP-2 and all GHSR-1a agonists. The critical distinction from GHRH is the receptor and second messenger system: GHRH activates GHRHR → Gs → cAMP → PKA, while GHRPs activate GHSR-1a → Gq → PLC → PKC. This pathway divergence is why combining GHRP-6 with a GHRH analog produces synergistic GH release — the two pathways converge on calcium-dependent vesicle fusion through different routes. Our GHRH vs GHRP article explains these dual pathways in depth.

Hypothalamic Actions

GHRP-6 also acts centrally within the hypothalamus:

• Stimulates GHRH neurons in the arcuate nucleus, increasing endogenous GHRH tone
• Antagonizes somatostatin signaling, reducing the inhibitory brake on GH release
• Activates NPY/AgRP neurons in the arcuate nucleus — this is the primary driver of GHRP-6's pronounced appetite-stimulating effects

This dual pituitary + hypothalamic action makes GHRP-6 a more potent GH secretagogue than its mechanism at either site alone would predict.

Ghrelin Mimicry and Appetite

GHRP-6 is a particularly strong ghrelin mimetic when it comes to orexigenic (appetite-stimulating) effects. While all GHRPs activate GHSR-1a, GHRP-6 appears to engage the hunger signaling components of ghrelin biology more robustly than GHRP-2 or ipamorelin.

The mechanism involves:

• GHSR-1a activation in the arcuate nucleus → NPY/AgRP neuron stimulation
• Downstream activation of orexigenic pathways in the lateral hypothalamus
• Possible modulation of reward circuits in the ventral tegmental area (Ghrelin signaling in VTA mediates reward-based feeding, 2015)

This appetite effect is a feature for some applications (recovery from illness, cancer cachexia) and a side effect for others.

Key Difference from GHRP-2

While GHRP-6 and GHRP-2 share the same receptor target (GHSR-1a) and the same fundamental signaling pathway, they differ in several clinically meaningful ways:

Appetite Stimulation

GHRP-6 produces markedly stronger hunger than GHRP-2. This is the single most obvious difference users of both peptides report, and it's supported by the preclinical literature. GHRP-6's activation of hypothalamic appetite circuits appears more pronounced, potentially due to differences in receptor binding kinetics or engagement of accessory signaling pathways.

GH Release Potency

Both peptides produce robust GH release at equivalent doses. GHRP-6 may produce slightly higher peak GH values in some studies, though this varies across populations and protocols. The difference is modest compared to the difference in appetite effects.

Side Effect Burden

GHRP-6 tends to cause:

• More pronounced appetite stimulation (sometimes intense hunger within 20 minutes)
• Comparable cortisol elevation to GHRP-2
• Similar prolactin stimulation

Cytoprotective Research

GHRP-6 has a more developed literature on cytoprotective and cardioprotective effects than GHRP-2, with extensive research from Cuban and international groups on its tissue-protective properties (covered in the Benefits section below).

GHRP-6 Dosing Protocols

Dose Range

Clinical and preclinical research on GHRP-6 has used a range of doses:

• 1 mcg/kg (~100 mcg): Standard dose used in many clinical studies. Produces robust GH release with moderate side effects.
• 2 mcg/kg (~150-200 mcg): Higher dose used in some protocols. Greater GH output but proportionally more appetite stimulation and cortisol elevation.
• 100-300 mcg per injection: The practical range, with most research centering on 100-200 mcg.

A pharmacokinetic study in nine healthy male volunteers characterized GHRP-6's absorption and distribution profile, confirming rapid absorption after subcutaneous injection with peak plasma concentrations within minutes (PK study of GHRP-6, 2012).

Timing

Like all GHRPs, GHRP-6 should be administered on an empty stomach for optimal GH response:

• Fasted state: 30-60 minutes before food, or 2+ hours after eating
• Why: Elevated glucose, insulin, and free fatty acids suppress the GH response to GHSR-1a activation
• Note: Given GHRP-6's strong appetite stimulation, timing it before a planned meal can be practical — the hunger hits approximately 20-30 minutes post-injection

Frequency

• 2-3 times daily in multi-dose protocols
• Common timing: Morning fasted, pre-workout (if training fasted), and before bed
• Minimum spacing: 3+ hours between doses to allow GHSR-1a resensitization

Desensitization

Like GHRP-2, continuous daily GHRP-6 use can lead to receptor desensitization and attenuated GH response over time. Cycling strategies (e.g., 5 on / 2 off, or periodic breaks) may help maintain receptor sensitivity.

Ready to buy? Compare verified vendors on our best GHRP-6 sources page, or browse all coupon codes for up to 50% off.

Benefits of GHRP-6

1. Pulsatile GH Release

The primary benefit of GHRP-6 is stimulating endogenous GH release in a pulsatile pattern that approximates natural physiology. Unlike exogenous GH injections (which create a flat, non-physiologic pharmacokinetic profile), GHRP-6 triggers the pituitary to release its own stored GH in bursts.

This pulsatile release pattern is important because GH's downstream effects — including IGF-1 production, lipolysis, and protein synthesis — are partially dependent on the pulsatile signal rather than continuous GH exposure.

2. Appetite Stimulation for Recovery

GHRP-6's potent orexigenic effects make it particularly relevant in research on:

• Cancer cachexia — Loss of appetite and muscle wasting in cancer patients
• Chemotherapy-associated anorexia — Similar to findings with GHRP-2 (GHRP-2 reverses chemotherapy anorexia, 2008)
• Recovery from illness or surgery — When increased caloric intake is beneficial
• Underweight conditions — Where appetite stimulation supports weight gain

The gastrointestinal effects of GHRP-6 have been characterized, including its stimulation of upper GI contractile activity and food intake (GHRP-2 GI effects in dogs, 2009).

3. Cytoprotective and Cardioprotective Effects

GHRP-6 has a substantial body of research on tissue-protective effects that extend beyond GH release:

Cardioprotection:

• GHRP-6 prevents doxorubicin-induced myocardial damage by activating prosurvival pathways (GHRP-6 prevents doxorubicin cardiotoxicity, 2024)
• The peptide has been studied for prevention of multiple organ failure in critical illness settings (GHRP-6 for multiple organ failure prevention, 2006)

Neuroprotection:

• Ghrelin pathway activation (via GHSR-1a) promotes neurologic recovery and neurogenesis after experimental stroke (Ghrelin promotes neurologic recovery post-stroke, 2025)
• GHRP-6 combined with EGF has been studied in a Phase I/II clinical trial for acute ischemic stroke (GHRP-6/EGF combination in stroke, 2024)

Cell Turnover:

• GHRP-6 has differential beneficial effects on cell turnover in the pituitary, hypothalamus, and heart — distinct from insulin's effects in the same tissues (GHRP-6 cell turnover effects, 2011)

4. Synergistic GH Release with GHRH

Like all GHRPs, GHRP-6 produces synergistic GH output when combined with GHRH analogs. This synergy has been extensively documented by Veldhuis et al. and is the scientific basis for GHRP + GHRH stacking protocols (Veldhuis et al., 2009).

For practical stacking strategies, see our Peptide Stacking Guide.

Side Effects

Appetite Stimulation (The Dominant Side Effect)

GHRP-6's most prominent side effect is intense hunger, typically onset within 20-30 minutes of injection. This is a direct consequence of GHSR-1a activation in hypothalamic appetite centers. The hunger is:

• Dose-dependent — Higher doses produce more intense appetite
• Transient — Usually lasts 30-60 minutes
• Difficult to ignore — Many report it as genuinely intense, beyond normal hunger
• More pronounced than other GHRPs — This is GHRP-6's distinguishing side effect

Cortisol Elevation

GHRP-6 stimulates the HPA axis similarly to GHRP-2, causing acute ACTH and cortisol release. At standard doses, the cortisol elevation is transient and typically within physiological ranges. However, repeated high-dose administration could have cumulative effects on cortisol dynamics.

Prolactin Elevation

A modest, dose-dependent increase in prolactin occurs with GHRP-6 administration. Like cortisol, this is generally transient at standard doses. Chronic elevation could theoretically impact libido and reproductive function, though this hasn't been well-characterized in long-term GHRP-6 studies.

Water Retention

Some reports describe mild water retention / bloating, likely related to GH-mediated effects on sodium handling.

Other Reported Effects

• Injection site reactions (mild, transient)
• Numbness or tingling in extremities (uncommon)
• Dizziness (rare, dose-dependent)
• Potential impact on blood glucose — GHSR-1a activation can influence insulin sensitivity

GHRP-6 vs GHRP-2: Quick Comparison

The core difference: GHRP-6 is the hungrier GHRP. If appetite stimulation is desirable (recovery, underweight, post-illness), GHRP-6 has an advantage. If hunger is unwanted, GHRP-2 or ipamorelin may be better choices.

For a much deeper head-to-head analysis, see our Hexarelin deep dive to understand where GHRP-6 sits relative to the most potent GHRP in the family.

Stacking GHRP-6 with GHRH Analogs

The Synergy Principle

The scientific rationale for combining GHRP-6 with a GHRH analog (CJC-1295, Sermorelin, etc.) is well-established:

• GHRP-6 activates GHSR-1a → Gq → PLC → PKC → intracellular calcium
• GHRH analog activates GHRHR → Gs → cAMP → PKA → calcium channel modulation
• Result: Both pathways converge on calcium-dependent GH vesicle exocytosis, producing synergistic output

Veldhuis et al. have documented that the GHRP + GHRH combination produces GH responses 3-10× greater than either peptide alone (Differential pulsatile secretagogue control, 2013).

CJC-1295 as Stacking Partner

CJC-1295 (with or without DAC) is the most commonly discussed GHRH analog for stacking with GHRP-6:

• CJC-1295 with DAC provides sustained GHRH receptor activation over days (Teichman et al., 2006)
• CJC-1295 without DAC (mod GRF 1-29) has a shorter duration, allowing more precise pulse timing
• The combination leverages dual-pathway synergy

For how CJC-1295 compares to Sermorelin as a GHRH stacking partner, see our CJC-1295 vs Sermorelin analysis.

Stacking Considerations

When combining GHRP-6 with GHRH analogs:

• Administer both peptides simultaneously for maximum synergy
• Maintain fasted state for optimal response
• Be aware that the combination may amplify both GH release and side effects (cortisol, hunger)
• The synergy is modulated by age, sex steroids, and body composition

Our Peptide Stacking Guide covers multi-peptide protocols in depth.

GHRP-6 in Stroke and Critical Illness Research

One of the most interesting areas of GHRP-6 research extends well beyond bodybuilding or anti-aging. Cuban research groups have extensively studied GHRP-6 for:

• Stroke therapy — A Phase I/II clinical trial combined GHRP-6 with recombinant EGF for acute ischemic stroke, representing a novel neuroprotective approach (Berlanga-Acosta et al., 2024)
• Dose-effect and therapeutic window assessment in preclinical stroke models using the rhEGF + GHRP-6 combination (Berlanga-Acosta et al., 2015)
• Multiple organ failure prevention in experimental models (Berlanga-Acosta et al., 2006)
• Acute lung injury and its progression to interstitial fibrosis (GHRP-6 ameliorates acute lung injury, 2025)

These applications leverage GHRP-6's cytoprotective properties — effects that appear to be at least partially independent of GH release and may involve direct GHSR-1a-mediated anti-inflammatory and anti-apoptotic signaling.